Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation

H Huynh, SP Choo, HC Toh, WM Tai… - Current Cancer Drug …, 2011 - ingentaconnect.com
Hepatocellular carcinoma (HCC) is the fifth most common and third deadliest malignancy.
Sorafenib has demonstrated 44% survival advantage over placebo and has emerged as a …
被引用次数：24 相关文章

Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation

H Huynh, SP Choo, HC Toh, WM Tai… - … cancer drug targets, 2011 - pubmed.ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the fifth most common and third deadliest malignancy.
Sorafenib has demonstrated 44% survival advantage over placebo and has emerged as a …

Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.

H Huynh, SP Choo, HC Toh, WM Tai… - Current Cancer Drug …, 2011 - europepmc.org
Hepatocellular carcinoma (HCC) is the fifth most common and third deadliest malignancy.
Sorafenib has demonstrated 44% survival advantage over placebo and has emerged as a …